Physician profile
Amber Clark
NPI 1992358485
$3,802.38
in general payments reported to CMS, 2019-2025
27 companies · $715 in 2025
The $715 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $542 · 2022: $655 · 2023: $1,064 · 2024: $826 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $724.52 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $697.18 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $590.86 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $306.58 | 2021-2025 | Airsupra, Farxiga |
| Amgen INC. | $177.10 | 2021-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $171.50 | 2021-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $144.41 | 2021-2024 | Glassia |
| Abbvie INC. | $142.26 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $139.97 | 2022-2023 | Quviviq |
| Boston Scientific Corporation | $102.66 | 2023-2024 | |
| Pfizer INC. | $99.26 | 2021-2025 | |
| Exact Sciences Corporation | $78.19 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $77.67 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.49 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $47.75 | 2021-2025 | Gvoke Hypopen |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31.85 | 2021-2022 | |
| Axsome Therapeutics, INC. | $29.26 | 2023 | Sunosi |
| Ardelyx, INC. | $23.56 | 2024 | Ibsrela |
| Vbi Vaccine (Delaware) INC. | $20.80 | 2022 | |
| Insulet Corporation | $18.81 | 2024 | Omnipod |
| Azurity Pharmaceuticals, INC. | $18.69 | 2023 | Edarbi |
| Globus Medical, INC. | $17.58 | 2022 | |
| Tosoh Bioscience, INC. | $17.34 | 2023 | |
| Sunovion Pharmaceuticals INC. | $16.24 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.12 | 2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $15.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.